Amilo-5MER is under clinical development by Galmed Pharmaceuticals and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome. According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Amilo-5MER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Amilo-5MER overview
Amilo-5MER is under development for the treatment of acute respiratory distress syndrome caused by coronavirus disease 2019, Crohn's disease, multiple sclerosis, rheumatoid arthritis and ulcerative colitis. The drug candidate is a 5 amino acid synthetic peptide MTADV (Methionine, Threonine, Alanine, Aspartic acid, Valine). It is a new chemical entity. It is administered through oral and subcutaneous route.
Galmed Pharmaceuticals overview
Galmed Pharmaceuticals is a clinical-stage drug development biopharmaceutical company. It primarily focuses on the development of innovative treatments for inflammatory diseases. The company’s main products are in various stages of clinical trials, including the ARMOR Phase 3 Study Programs, and include aramchol meglumine and Amilo-5MER. The company’s products are designed for patients suffering from inflammatory diseases, aiming to provide effective, safe, and tolerable lifetime medicine. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Galmed Pharmaceuticals is headquartered in Tel Aviv, Israel.
For a complete picture of Amilo-5MER’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.